STOCK TITAN

Moderna Inc - MRNA STOCK NEWS

Welcome to our dedicated news page for Moderna (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Moderna's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Moderna's position in the market.

News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
partnership
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.94%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.18%
Tags
covid-19
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.18%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none
Moderna Inc

Nasdaq:MRNA

MRNA Rankings

MRNA Stock Data

40.26B
344.86M
9.63%
73.16%
5.6%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Cambridge

About MRNA

moderna is pioneering messenger rna therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. this breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions. moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. the company plans to develop and commercialize its innovative mrna drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients. based in cambridge, massachusetts, moderna is privately held and was founded in 2010 by flagship venturelabs in association with leading scientists from boston children’s hospital a